Phoenix Laboratories has acquired an exclusive license to market, distribute and sell all of Cytodyne Technologies' products, including its controversial ephedra-based supplement Xenadrine EFX, following the formation of a new partnership between the two companies.
All business and operations regarding Cytodyne will now be conducted and handled, under the Cytodyne name, at Phoenix Labs' current headquarters in Hicksville, New York, under the agreement which formally went into effect last month. The products will also continue to be sold under the Cytodyne brand name.
Commenting on the new partnership, Mel Rich, CEO of Pheonix Labs, said the company was "extremely pleased and proud to have forged this new relationship." He added that Pheonix Labs "looked forward to continuing in Cytodyne's successful footsteps and doing even greater things together."
Robert Chinery, founder of Cytodyne, echoed Rich, adding that the company expected Phoenix Labs to "maintain the same high standards and continuity in the manufacturing, distribution, marketing, advertising and sales of Cytodyne brand products, while adding to the mix their cutting-edge product development team."
Despite the changes, Phoenix says any questions or inquiries regarding the future operations or distribution of any Cytodyne brand products should still be directed to Cytodyne.
Cytodyne's Xenadrine RFA-1 supplement was implicated in the heat stroke death of Baltimore Orioles pitcher Steve Bechler in February. Earlier this month Cytodyne was ordered to repay consumers of Xenadrine RFA-1 in California around $12,536, 820.00, as "money obtained by means of unlawful practice". The company said at the time it would appeal the ruling.